Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2024-08-30 Declaration of Voting R…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Amended number of shares and votes in Abliva AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly announces an 'Amended number of shares and votes in Abliva AB (publ)' due to the conversion of a convertible loan. This directly relates to a change in the company's capital structure and outstanding shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). Although it is a short announcement, the core subject matter is a capital structure change, not just the announcement of a report, making SHA a more specific fit than RPA or RNS. The document states the total number of shares has increased by 262,500,000.
2024-08-30 English
Ändring av antal aktier och röster i Abliva AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short announcement titled "Ändring av antal aktier och röster i Abliva AB (publ)" (Change in the number of shares and votes in Abliva AB (publ)). It explicitly states that the number of shares increased due to the conversion of a convertible loan and provides the new total number of shares and votes as of the last trading day of the month. This type of announcement, detailing a change in the capital structure (specifically related to outstanding shares), aligns best with the 'Share Issue/Capital Change' category (SHA). Although it is a regulatory disclosure, SHA is more specific than the general 'RNS' fallback. The document is short and serves as a notification of a capital event, not a comprehensive report.
2024-08-30 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-June 2024, published by Abliva. It contains detailed financial statements (income statement highlights), management commentary on business performance, clinical trial updates (FALCON study), and strategic outlook. It is a comprehensive report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2024
2024-08-22 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Report Interim' and covers the period 'January - June 2024'. It contains detailed financial information, including net revenues, loss before tax, and loss per share for both the second quarter and the first half of the year. It also includes a management discussion (CEO letter) and operational updates regarding clinical trials (FALCON study). This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-08-22 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding for 'Hadean Ventures AS' concerning 'Abliva AB'. It explicitly uses the structure of a 'major shareholding notification', showing 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (25.47064%). This content directly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2024-08-16 English
Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Capital/Financing Update Classification · 1% confidence The document is titled as a 'Press Release' and announces a specific corporate action: the conversion of a convertible loan into shares triggered by a positive study analysis. It details the financial impact (proceeds raised, increase in share capital, and number of shares) and provides contact information for Investor Relations. This type of announcement, which is a formal update on financing/capital structure changes, fits best under the 'Capital/Financing Update' category (CAP). Although it is a press release, the core subject matter is financing, making CAP more specific than the general 'RNS' fallback. The document length is short (3693 chars) and it includes an attachment link, but the primary content is the announcement itself, not just a notice that a report is attached, thus it is classified by content.
2024-07-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.